Make Informed Investment Decisions with Affordable Access to Experts
Checking in with an expert on the immuno-oncology landscape in metastatic triple-negative breast cancer and where IMMU-132 fits in after the 2017 SABCS conference last weekTicker(s): IMMU, MRK
Name: Dr Daniel P Silver - MD, PhD
Institution: Sidney Kimmel Cancer Center
- Leader, Breast Program Sidney Kimmel Cancer Center & Associate Professor and Director, Basic Science and Research in Medical Oncology
- Treats ~400 patients with breast cancer/year, currently treats ~12 with metastatic triple-negative breast cancer and has treated hundreds with mTNBC in the last 20 years.
- Attended SABCS and very familiar with the data from the Phase 2 trial for Sacituzumab Govitecan (IMMU-132)
Please describe your clinical practice; roughly how many patients with triple-negative breast cancer do you currently treat
What were your impressions on the data presented at SABCS for Sacituzumab govitecan (IMMU-132)?Added By: c_admin
If approved, how do you see IMMU-132 competing in the IO landscape? How does it compare to Keytruda?Added By: c_admin
On a scale of 1-10, 10 being extremely excited, where would you rate your level of excitement for this drug?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.